Long-term efficacy and safety of upadacitinib treatment in patients with Crohn´s disease: One-year results of the ongoing phase 2 CELEST open-label extension study

(1) Amsterdam University Medical Center,Amsterdam,Netherlands

(2) Hospital Clínic Barcelona, IDIBAPS, CIBERehd,Barcelona,Spain

(3) CHU de Liège et Université de Liège,Liège,Belgium

(4) AbbVie Inc.,Chicago,United States

(5) Mayo Clinic,Rochester,United States



This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019